Member Info for Dibs61

I agree this IS a positive article in the Telegraph. It’s a relief for investors who are desperate for some good news. So I’m not here to p*ss on anyone’s parade but I would say this - a precautionary note. MM’s read these articles (and of course RNS’s) for the companies they cover. So they know there will be demand on Monday morning. Which means yes they will mark the price up readily. It will get the blood pumping. But my advice is do NOT buy first thing. Wait. They still haven’t got a single order yet let alone any sales. So, if you’re not careful you’ll buy at 40p plus in a rush of Adrenalin and then find the price slips back again as smart money takes their profit. Sure there will still be sore placees out there too looking to take opportunity to take profit.

So look, ignore all the rabid ramping and make your purchases smartly. Buy on a dip not spike. I think there’s still time here before the action starts. Remember the health spokesman said the large purchases would be made ‘before the end of the year’. Doesn’t sound like next week does it? Analyse the words carefully and not just the bits you want to hear.

There has been NO RNS yet to say Acacia are out.

Now NT to buy any quantity and I can get dummy sell of 34.88

I watched Boris announcement this morning and no mention of antibody testing whatsoever. Purely talking of major ramp up in Antigen tests. Its not at the forefront of their thinking yet and no guarantee it will be. I don't trust this government. They have flip flopped on practically everything during the pandemic. I wouldn't put it past them to do the same here.

Courtesy of firtashia on advfn:

FY20 forward EPS estimates nudged up to 3.10p, according to Stockopedia.

If that EPS figure proves correct then that puts EKF on a current year PE ratio of 14.6. I would suggest that is quite cheap. If you add in the news that the UK government is expanding testing capacity to 500k tests per day by October then this looks even cheaper.

Courtesy of wan on advfn:

Indicative? -

Abbott tops Q2 estimates aided by 233.6% jump in molecular diagnostics

PUBLISHED
July 16, 2020

Abbott's diagnostics sales grew 7% in the second quarter on an organic basis.

"Similar to what we saw in medical device procedures, testing volumes in our underlying diagnostics business, which excludes COVID-19 tests, rebounded to approximately 90% of pre-COVID levels by the end of the second quarter," Ford said.

When it comes to COVID-19 tests, molecular diagnostics were up 241% and rapid diagnostics increased 11%, respectively. Strong demand for Abbott's lab-based tests for the coronavirus resulted in diagnostics sales of $283 million in the quarter, while Abbott's point-of-care COVID-19 molecular test on its ID NOW platform helped drive rapid diagnostics sales of $180 million in the quarter.

"We think COVID testing will stick around," commented Ford.

Abbott's consumer-facing businesses, such as diabetes care, nutrition, and established pharmaceuticals, have continued to be "resilient" amid the pandemic collectively growing 9% in the first half of the year, according to Ford.

Abbott's financial health remains strong. The company ended the second quarter with about $5 billion in cash and short-term investments, an increase of more than $1 billion compared to the end of the first quarter.

hTTps://www.medtechdive.com/news/abbott-q2-tops-wall-street-estimates-buoyed-by-covid-19-test-surge/581728/

Courtesy of wan on advfn:

Indicative? -

Abbott tops Q2 estimates aided by 233.6% jump in molecular diagnostics

PUBLISHED
July 16, 2020

Abbott's diagnostics sales grew 7% in the second quarter on an organic basis.

"Similar to what we saw in medical device procedures, testing volumes in our underlying diagnostics business, which excludes COVID-19 tests, rebounded to approximately 90% of pre-COVID levels by the end of the second quarter," Ford said.

When it comes to COVID-19 tests, molecular diagnostics were up 241% and rapid diagnostics increased 11%, respectively. Strong demand for Abbott's lab-based tests for the coronavirus resulted in diagnostics sales of $283 million in the quarter, while Abbott's point-of-care COVID-19 molecular test on its ID NOW platform helped drive rapid diagnostics sales of $180 million in the quarter.

"We think COVID testing will stick around," commented Ford.

Abbott's consumer-facing businesses, such as diabetes care, nutrition, and established pharmaceuticals, have continued to be "resilient" amid the pandemic collectively growing 9% in the first half of the year, according to Ford.

Abbott's financial health remains strong. The company ended the second quarter with about $5 billion in cash and short-term investments, an increase of more than $1 billion compared to the end of the first quarter.

hTTps://www.medtechdive.com/news/abbott-q2-tops-wall-street-estimates-buoyed-by-covid-19-test-surge/581728/

And calling 34p as the bottom. It’s tested it a few times and bounced every time.

We are overdue a rally

Oh and btw apparently you said the CEO stated "categorically" there would be NO fundraising in the next year. Only six weeks ago. Now that is an 'LOL' if ever I saw one xxx

No riddler I didn't apologise because no apology required. I actually posted to congratulate you on the SP rise which, at the time, you gracefully accepted but now you want to re-package it. Oh well never mind. Waiting for you to do the same on my successes.

Why would you buy now when you can buy cheaper tomorrow or the next day? Buying @ 5/6p is going to make your bagging/percentage gains much larger than buying between say 9/10p.

So that means 6's coming soon

JUst can't believe this situation!

Frustratingly slow to exit aren't they this lot. Have forced me to rethink my strategy. I've decided to keep some in for the results. Gulp. Could be 10p or £1 in two weeks time!

We have a very good newsflow and in the near term. Which should be universally positive. I won't list it all we know what it is.

Putting my head on the block I see very little downside from here. The sell on news brigade have finished we just need a fresh trigger through one piece of affirming news and that should set us shooting back up toward £3 and beyond again.

Just a matter of time IMO. Covid is not going anywhere.

For a move back north again. Just need one or two bigger buys.

Been following progress here. I thought you said categorically they were funded here for a year? That was just a few weeks back I'm sure.

Yes jolly and there were 'prominent' (thats a kind way to put it) posters here last week - you know who you are - stating categorically that it was going to be blue skies all the way following the meeting last Friday. Blue all the way this week the price was going only one way - up. Apparently you couldn't pick stock up around the placing price. Such a plethora of b*lls*it.

You have to learn how to read ALL RNS's and understand exactly what they are saying and what they are not saying. You have to put aside all 'feelings'. Never fall in love with a stock. It will kill you if you do. Make a dispassionate conclusion of the content in announcements. And most of all Be prepared to change your strategy. They have given out enough clues up to this point and AIM is NOT a patient market.

For this to get to a pound now it will have to make a £178m MC. That is roughly the current NCYT MC and they are selling all over the world and have several months sales already under their belt. That is a big ask in terms of whether there will be the demand when antibody levels are dropping off sharply after a few months. And whether management credibility can be restored.

I think another point to consider is general sentiment. Quite a number of Smallcap pundits, "experts" *coughs* called the Covid stocks a bubble and that has had a large impact. This idea that the bubble has burst, the 'everything is ok' and yep these companies are a five minute wonder.

That MAY prove to be true in a lot of cases - especially where its jam tomorrow tests being developed scenarios. But NCYT IS different. First mover advantage. Throwing off loads of cash. It's all about the market perception of HOW LONG IT WILL LAST. That is the crucial bit. When you want to value the company whether its £200M or £500M you want that longer term visibility of sales and I think thats the missing bit now which is holding back a rerating. No one doubts they are making lots of sales but how long for? I think we will have a clearer answer in the next few weeks.

JH - except that the market doesn't always get it right. Thats the opportunity to make money, especially in smaller stocks.
Sentiment dictates the price. If sentiment just isn't there or is poor then it will be undervalued. If it's frothy it may be overvalued.

Suppose he (JW) has sold. So what?? Who cares. We make our own decisions DON"T we?

And why would he lose any credibility? I say good luck to the bloke if he has taken a profit. NOTHING wrong with that.

I find it amusing that so much stall is being held in what one bloke does. And why people are angry with him for selling? It really is bizarre behaviour.